Drugs / 177Lu-PSMA-I&T
177Lu-PSMA-I&T
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04886986 | Jun 2021 → Dec 2027 expected | prostate cancer | Weill Medical College of Cornell University | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05896371 | Mar 2028 → Mar 2033 expected | metastatic malignant neoplasm, metastatic prostate carcinoma | CHU de Quebec-Universite Laval | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04188587 | Jan 2019 → Aug 2020 | castration-resistant prostate carcinoma | Nanjing First Hospital, Nanjing Medical University | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05204927 | Feb 2022 → Aug 2024 overdue | metastatic prostate carcinoma | Curium US LLC | Active not recruiting | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07316686 Background | Jun → Sep 2026 expected | prostate adenocarcinoma | Cancer Institute of the State of São Paulo | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06343038 Comparator | Feb 2024 → Jun 2028 expected | castration-resistant prostate carcinoma | University Hospital, Basel, Switzerland | Recruiting | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-09-17 | Novartis Pharmaceuticals | Novartis reports positive health-related quality of life data for 177Lu-PSMA-617 radioligand therapy in patients with advanced prostate cancer at ESMO 2021 novartis.com ↗ |
| 2021-06-03 | Novartis Pharmaceuticals | Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study novartis.com ↗ |
| 2021-03-23 | Novartis Pharmaceuticals | Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer novartis.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu-PSMA-I&T | “177Lu-PSMA-I&T” NCT07316686 ↗ |
| Known as | 177Lu-PSMA | “Lutetium-177 (177Lu)-PSMA (LuPSMA) is a novel and highly targeted systemic RLT for progressive mCRPC.” NCT04188587 ↗ |
| Known as | LuPSMA | “Lutetium-177 (177Lu)-PSMA (LuPSMA) is a novel and highly targeted systemic RLT for progressive mCRPC.” NCT04188587 ↗ |
| Known as | Lutetium 177Lu-PSMA-I&T | “This is a prospective, open-label, multi-center, randomized, Phase 3 study evaluating Lutetium 177Lu-PSMA-I&T as treatment compared to standard of care hormone therapy in men...” NCT05204927 ↗ |
| Known as | PSMA-I＆T | “177 Lu -labeled PSMA ligand(PSMA-I＆T)” NCT04188587 ↗ |
| Modality | Other / unclassified | “Lutetium-177 (177Lu)-PSMA (LuPSMA) is a novel and highly targeted systemic RLT for progressive mCRPC.” NCT04188587 ↗ |
| Route | Intravenous | “All patients were intravenous injected with single dose 2.0-8.0 GBq.” NCT04188587 ↗ |